World Health Organization 2017. http://who.int/mediacentre/factsheets/fs369/en/.
Cipriani, A. et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 388, 881–890 (2016).
Article PubMed CAS Google Scholar
Yang, Y. et al. The extrinsic coagulation pathway: a biomarker for suicidal behavior in major depressive disorder. Sci. Rep. 6, 32882 (2016).
Article PubMed PubMed Central CAS Google Scholar
Fava, M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 53, 649–659 (2003).
Article PubMed Google Scholar
Zheng, P. et al. Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells. J. Affect Disord. 195, 75–81 (2016).
Article PubMed CAS Google Scholar
Strawbridge, R., Young, A. H. & Cleare, A. J. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr. Dis. Treat. 13, 1245–1262 (2017).
Article PubMed PubMed Central CAS Google Scholar
Rotroff, D. M. et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Transl. Psychiatry 6, e894 (2016).
Article PubMed PubMed Central CAS Google Scholar
Rzezniczek, S. et al. Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. Transl. Psychiatry 6, e827 (2016).
Article PubMed PubMed Central CAS Google Scholar
Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796 (2016).
Article PubMed CAS Google Scholar
Pan, J. et al. Ipsilateral hippocampal proteomics reveals mitochondrial antioxidative stress impairment in cortical-lesioned chronic mild stressed rats. Curr. Mol. Med. 14, 1186–1196 (2014).
Article PubMed CAS Google Scholar
Zheng, P. et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol. Cell. Proteom.: MCP 12, 207–214 (2013).
Article CAS Google Scholar
Zheng, P. et al. A novel urinary metabolite signature for diagnosing major depressive disorder. J. Proteome Res. 12, 5904–5911 (2013).
Article PubMed CAS Google Scholar
Xu, H. B. et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int. J. Neuropsychopharmacol. 15, 1413–1425 (2012).
Article PubMed CAS Google Scholar
Mu, J. et al. Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model. Neurosci. Lett. 416, 252–256 (2007).
Article PubMed CAS Google Scholar
Xu, F. et al. Macaques exhibit a naturally-occurring depression similar to humans. Sci. Rep. 5, 9220 (2015).
Article PubMed PubMed Central CAS Google Scholar
Weckmann, K., Labermaier, C., Asara, J. M., Muller, M. B. & Turck, C. W. Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates. Transl. Psychiatry 4, e481 (2014).
Article PubMed PubMed Central CAS Google Scholar
Nutt, D. J. et al. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 67(Suppl 6), 46–49 (2006).
PubMed Google Scholar
Milak, M. S. et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol. Psychiatry 21, 320–327 (2016).
Article PubMed CAS Google Scholar
Rajkowska, G. & Stockmeier, C. A. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr. Drug. Targets 14, 1225–1236 (2013).
Article PubMed PubMed Central CAS Google Scholar
Paterson, R. W. et al. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl. Psychiatry 4, e419 (2014).
Article PubMed PubMed Central CAS Google Scholar
Wiers, C. E. et al. Effects of depressive symptoms and peripheral DAT methylation on neural reactivity to alcohol cues in alcoholism. Transl. Psychiatry 5, e648 (2015).
Article PubMed PubMed Central CAS Google Scholar
Voyle, N. et al. Blood metabolite markers of neocortical amyloid-beta burden: discovery and enrichment using candidate proteins. Transl. Psychiatry 6, e719 (2016).
Article PubMed PubMed Central CAS Google Scholar
Yamagata, H. et al. Altered plasma protein glycosylation in a mouse model of depression and in patients with major depression. J. Affect Disord. 233, 79–85 (2017).
Article PubMed CAS Google Scholar
Ren, J. et al. Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis. Psychoneuroendocrinology 86, 17–24 (2017).
Article PubMed CAS Google Scholar
Liu, M. L. et al. Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study. J. Transl. Med. 13, 226 (2015).
Article PubMed PubMed Central CAS Google Scholar
Wang, W. et al. Targeted metabolomic pathway analysis and validation revealed glutamatergic disorder in the prefrontal cortex among the chronic social defeat stress mice model of depression. J. Proteome Res. 15, 3784–3792 (2016).
Article PubMed CAS Google Scholar
Xia, J. & Wishart, D. S. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr. Protoc. Bioinforma. 55, 14.10. 11–14.10.91 (2016).
Article Google Scholar
Park, M., Pyun, J. C., Akter, H., Nguyen, B. T. & Kang, M. J. Evaluation of a specific diagnostic marker for rheumatoid arthritis based on cyclic citrullinated peptide. J. Pharm. Biomed. Anal. 115, 107–113 (2015).
Article PubMed CAS Google Scholar
Gong, Q. et al. Network-level dysconnectivity in drug-naive first-episode psychosis: dissociating transdiagnostic and diagnosis-specific alterations. Neuropsychopharmacology 42, 933–940 (2017).
Gibson, J. et al. Assessing the presence of shared genetic architecture between Alzheimer’s disease and major depressive disorder using genome-wide association data. Transl. Psychiatry 7, e1094 (2017).
Article PubMed PubMed Central CAS Google Scholar
Hirschfeld, R. M. Differential diagnosis of bipolar disorder and major depressive disorder. J. Affect Disord. 169(Suppl 1), S12–S16 (2014).
Article PubMed Google Scholar
Lasalvia, A. et al. Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey. Lancet (Lond., Engl.) 381, 55–62 (2013).
Article Google Scholar
Gadad, B. S. et al. Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. J. Affect Disord. 233, 3–14 (2017).
Article PubMed CAS Google Scholar
Milaneschi, Y. et al. Polygenic dissection of major depression clinical heterogeneity. Mol. Psychiatry 21, 516–522 (2016).
Article PubMed CAS Google Scholar
Leuchter, A. F., Hunter, A. M., Krantz, D. E. & Cook, I. A. Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder. Dialog-. Clin. Neurosci. 16, 525–537 (2014).
Google Scholar
Helton, S. G. & Lohoff, F. W. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics 16, 541–553 (2015).
Article PubMed CAS Google Scholar
Kato, T. A. et al. Neurotransmitters, psychotropic drugs and microglia: clinical implications for psychiatry. Curr. Med. Chem. 20, 331–344 (2013).
PubMed CAS Google Scholar
Zhou, X. et al. Metabolomics identifies perturbations in amino acid metabolism in the prefrontal cortex of the learned helplessness rat model of depression. Neuroscience 343, 1–9 (2017).
Article PubMed CAS Google Scholar
Wang, L. et al. Serotonin-1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry 16, 319 (2016).
Article PubMed PubMed Central CAS Google Scholar
Zhou J. et al. Quantitative proteomic analysis reveals molecular adaptations in the hippocampal synaptic active zone of chronic mild stress-unsusceptible rats. Int. J. Neuropsychopharmacol. 19 (2015) doi: 10.1093/ijnp/pyv100.
Wu, Y. et al. Metabolomic analysis reveals metabolic disturbances in the prefrontal cortex of the lipopolysaccharide-induced mouse model of depression. Behav. Brain. Res. 308, 115–127 (2016).
Article PubMed CAS Google Scholar
Liu, L. et al. The identification of metabolic disturbances in the prefrontal cortex of the chronic restraint stress rat model of depression. Behav. Brain. Res. 305, 148–156 (2016).
Article PubMed CAS Google Scholar
Mota, R. et al. Interleukin-1beta is associated with depressive episode in major depression but not in bipolar disorder. J. Psychiatr. Res. 47, 2011–2014 (2013).
Article PubMed Google Scholar
Motovsky, B. & Pecenak, J. Psychopathological characteristics of bipolar and unipolar depression - potential indicators of bipolarity. Psychiatr. Danub. 25, 34–39 (2013).
PubMed Google Scholar
Cardoso de Almeida, J. R. & Phillips, M. L. Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives. Biol. Psychiatry 73, 111–118 (2013).
Article PubMed Google Scholar
Zheng, P. et al. Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC-MS-based metabonomics. Transl. Psychiatry 6, e955 (2016).
Article PubMed PubMed Central CAS Google Scholar
Zheng, P. et al. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J. Proteome Res. 11, 1741–1748 (2012).
Article PubMed CAS Google Scholar
Xu, H. B. et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res. 200, 1054–1057 (2012).
Article PubMed CAS Google Scholar
Wu, D. et al. Identification and validation of argininosuccinate synthase as a candidate urinary biomarker for major depressive disorder. Clin. Chim. Acta 451, 142–148 (2015).
Article PubMed CAS Google Scholar
Song, Y. R. et al. Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder. Braz. J. Med. Biol. Res.=Rev. Bras. De. Pesqui. Med. e Biol. / Soc. Bras. De. Biofisica [Et. al] 48, 973–982 (2015).
CAS Google Scholar
Xu, X. J. et al. 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. Mol. Biosyst. 10, 813–819 (2014).
Article PubMed CAS Google Scholar
Chen, J. J. et al. Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. Sci. Rep. 4, 5855 (2014).
Article PubMed PubMed Central CAS Google Scholar
Chen, J. J. et al. Sex-specific urinary biomarkers for diagnosing bipolar disorder. PLoS. One. 9, e115221 (2014).
Article PubMed PubMed Central CAS Google Scholar
Pehrson, A. L. & Sanchez, C. Altered gamma-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Des. Dev. Ther. 9, 603–624 (2015).
Article CAS Google Scholar
Taylor, S. F., Demeter, E., Phan, K. L., Tso, I. F. & Welsh, R. C. Abnormal GABAergic function and negative affect in schizophrenia. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 39, 1000–1008 (2014).
Article CAS Google Scholar
Rudenko, A. et al. Loss of cyclin-dependent kinase 5 from parvalbumin interneurons leads to hyperinhibition, decreased anxiety, and memory impairment. J. Neurosci.: Off. J. Soc. Neurosci. 35, 2372–2383 (2015).
Article CAS Google Scholar
Shabel, S. J., Proulx, C. D., Piriz, J. & Malinow, R. Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment. Sci. (New Y., NY) ; 345, 1494–1498 (2014).
Article CAS Google Scholar
Setoyama, D. et al. Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients—a multicenter pilot analysis. PLoS. One. 11, e0165267 (2016).
Article PubMed PubMed Central CAS Google Scholar
Mann, J. J. et al. Anxiety in major depression and cerebrospinal fluid free gamma-aminobutyric acid. Depress Anxiety 31, 814–821 (2014).
Article PubMed PubMed Central CAS Google Scholar
Abdallah, C. G. et al. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 25, 1082–1090 (2015).
Article CAS Google Scholar
Petty, F. GABA and mood disorders: a brief review and hypothesis. J. Affect Disord. 34, 275–281 (1995).
Article PubMed CAS Google Scholar
Kunugi, H., Hori, H. & Ogawa, S. Biochemical markers subtyping major depressive disorder. Psychiatry Clin. Neurosci. 69, 597–608 (2015).
Article PubMed Google Scholar
Zhao, L. et al. In vivo study on the neurotransmitters and their metabolites change in depressive disorder rat plasma by ultra high performance liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B. Anal. Technol. Biomed. Life. Sci. 988, 59–65 (2015).
Article CAS Google Scholar
Lake, C. R. et al. High plasma norepinephrine levels in patients with major affective disorder. Am. J. Psychiatry 139, 1315–1318 (1982).
Article PubMed CAS Google Scholar
Klempan, T. A. et al. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol. Psychiatry 14, 175–189 (2009).
Article PubMed CAS Google Scholar
Fakhoury, M. Revisiting the serotonin hypothesis: implications for major depressive disorders. Mol. Neurobiol. 53, 2778–2786 (2016).
Article PubMed CAS Google Scholar
Weng, R. et al. Metabolomics approach reveals integrated metabolic network associated with serotonin deficiency. Sci. Rep. 5, 11864 (2015).
Article PubMed PubMed Central Google Scholar
Havelund, J. F., Andersen, A. D. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J. Neurochem. 142, 756–766 (2017).
Page 2
Variables
Cohort 1
Cohort 2
HC
MDD
Pa
HC
MDD
BD
Pa
Sample size
50
50
–
40
49
30
–
Sex (M/F)
25/25
24/26
0.841
22/18
23/26
13/17
0.593
Age (years) b
36.9±1.3
38.3±1.6
0.503
36.8±1.6
37.7±1.7
35.8±10.7
0.249
BMIb
22.4±0.73
22.0±0.39
0.553
21.7±0.7
22.5±0.7
22.4±3.4
0.264
HDRS scores
0.4±0.1
24.6±0.5
<0.01
0.3±0.1
23.3±0.5
16.7±10.5
<0.01
BD-I
–
–
–
–
–
18
–
BD-II
–
–
–
–
–
12
–
Course (Month)
–
17.4±2.2
–
–
41.6±9.8
64.9±15.1
–
Medication (Y/N)
N
N
–
–
38/11
19/11
–
SSRI(Y/N)
N
N
–
N
29/20
10/20
–
SNRI (Y/N)
N
N
–
N
9/40
N
–
Mood stabilizers (Y/N)
N
N
–
N
N
5/25
–
Atypical antipsychotics(Y/N)
N
N
–
N
N
4/26
–
HC healthy controls, MDD major depressive disorder, BD bipolar disorder, Y/N Yes/No, M/F male/female, HDRS Hamilton depression rating scale, BMI body mass index, SSRI selective serotonin reuptake inhibitors, SNRI serotonin noradrenalin reuptake inhibitors
a Two-tailed Student’s test or one-way ANOVA for continuous variables (age, BMI, and HDRS scores); Chi-square analysis was used for categorical variables (sex)
